Essex Bio-Technology will showcase several key ophthalmology products at the APAO 2026 Annual Meeting of the Asia-Pacific Academy of Ophthalmology (APAO 2026)

Hong Kong, January 22, 2026

Essex Bio-Technology Limited (“Essex Bio-Technology” or “the Group,” stock code: 1061.HK) is pleased to announce that the Group will participate inFebruary 5-8, 2026Inthe 2026 Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held at the Hong Kong Convention and Exhibition Centre. This marks the second consecutive year the Group has participated in APAO, reflecting its long-term commitment and investment in the ophthalmology field across the Asia-Pacific region.

During the conference, Essex Bio-Technology will set up a dedicated booth to highlight its core products from the ophthalmology portfolio and pipeline, engaging in in-depth discussions with ophthalmologists, healthcare professionals, and industry partners from the Asia-Pacific region.

At APAO 2026, the Group will focus on showcasing the following two core products:

1. EB12-20145P (Bevacizumab)EB12-20145P continues to demonstrate strong momentum in clinical development. The project has been selected for poster presentation at the conference, where clinical progress and research insights will be shared with the international ophthalmology community. Poster presentation details: https://2026.apaophth.org/program-schedule/?code=0464

2. Single-dose Beifushu® Eye DropsYisheng Biotech achieves a significant milestone as its single-dose Beifushu® Eye Drops are officially launched in Singapore. The first batch of products has been introduced at the Singapore National Eye Centre (SNEC), a leading tertiary eye care institution in the region. The company plans to expand further into additional medical institutions and gradually extend to the Asia-Pacific region in compliance with regulatory and commercial factors.

The group's participation in APAO 2026, the advancement of EB12-20145P in clinical trials, and the expansion of single-dose Beifushu® Eye Drops into the Asia-Pacific region highlight Yisheng Biotech’s commitment todriving ophthalmic advancements through clinically validated first-in-class and best-in-class treatment solutionswhile deepening collaboration with top ophthalmic institutions and professionals across the Asia-Pacific region.

We sincerely invite all participants to visit the Yisheng Biotech boothto gain deeper insights into the group's ophthalmic solutions, clinical applications, and strategic development within the Asia-Pacific region.

Regarding Essex Bio-Technology (Stock Code: 1061.HK)

Yisheng Biotech is a biopharmaceutical company specializing in the research, production, and sales of genetically engineered drugs such as b-bFGF. It markets six genetically engineered drugs in China, including Beifushu®, Beifuj®, and Beifuxin®. Additionally, the company boasts a diversified portfolio that includes a series of preservative-free single-dose eye drops and Shilixun® Lecithin Iodine Capsules, primarily used for wound healing and disease treatment in prescription ophthalmology and dermatology. These products are marketed and sold in over 14,100 hospitals nationwide, supported by the company’s 46 regional offices across China. Backed by its R&D platform in growth factor and antibody technology, Yisheng Biotech maintains a robust pipeline spanning multiple clinical stages and covering a wide range of therapeutic areas and indications.

42K Views